Dexcom (DXCM) valuation
Dexcom P/E ratio history
Dexcom trades at 32.4 times its earnings over the last twelve months and 27.3 times the earnings analysts expect over the next twelve. At its last 7 fiscal year ends its P/E ranged from 31.8 (year to Dec 2025) to 253.3 (year to Dec 2021), with a median of 95.5.
| Fiscal year ended | Price | EPS | P/E | Forward P/E |
|---|---|---|---|---|
| Dec 31, 2025 | $66.37 | $2.09 | 31.8 | 28.0 |
| Dec 31, 2024 | $77.77 | $1.42 | 54.8 | 39.7 |
| Dec 31, 2023 | $124.09 | $1.30 | 95.5 | 75.7 |
| Dec 31, 2022 | $113.24 | $0.82 | 138.1 | 112.2 |
| Dec 31, 2021 | $134.24 | $0.53 | 253.3 | 156.9 |
| Dec 31, 2020 | $92.43 | $1.33 | 69.5 | — |
| Dec 31, 2019 | $54.69 | $0.27 | 202.5 | — |
| Dec 31, 2018 | $29.95 | -$0.36 | n/m | — |
| Dec 31, 2017 | $14.35 | -$0.15 | n/m | — |
| Dec 31, 2016 | $14.93 | -$0.19 | n/m | — |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
Dexcom valuation against its peers
| Company | Market value | P/E | Forward P/E | Price / sales |
|---|---|---|---|---|
| DexcomDXCM | $31.1B | 32.4 | 27.3 | 6.1 |
| ResMedRMD | $33.4B | 20.9 | 18.6 | 5.9 |
| GE HealthCareGEHC | $34.6B | 16.2 | 14.3 | 1.6 |
| Idexx LaboratoriesIDXX | $43.5B | 38.7 | 34.9 | 9.6 |
| SterisSTE | $22.2B | 27.8 | 19.8 | 3.7 |
| Zimmer BiometZBH | $18.3B | 22.9 | 10.8 | 2.2 |
| Edwards LifesciencesEW | $53.0B | 52.9 | 28.9 | 8.1 |
| Becton DickinsonBDX | $54.5B | 74.5 | 15.1 | 2.6 |
| RevvityRVTY | $17.5B | 75.1 | 27.9 | 6.0 |
| Peer median | 33.3 | 19.2 | 4.8 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: DXCM financials · DXCM returns
No forecast, no recommendation. This page describes Dexcom from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.